Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations

  • Shirin Tavakoli
  • , Otto Kalevi Kari
  • , Tiina Turunen
  • , Tatu Lajunen
  • , Mechthild Schmitt
  • , Julia Lehtinen
  • , Fumitaka Tasaka
  • , Petteri Parkkila
  • , Joseph Ndika
  • , Tapani Viitala
  • , Harri Alenius
  • , Arto Urtti
  • , Astrid Subrizi*
  • *Korresponderande författare för detta arbete

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

53 Citeringar (Scopus)

Sammanfattning

The vitreous humor is the first barrier encountered by intravitreally injected nanoparticles. Lipid-based nanoparticles in the vitreous are studied by evaluating their diffusion with single-particle tracking technology and by characterizing their protein coronae with surface plasmon resonance and high-resolution proteomics. Single-particle tracking results indicate that the vitreal mobility of the formulations is dependent on their charge. Anionic and neutral formulations are mobile, whereas larger (>200 nm) neutral particles have restricted diffusion, and cationic particles are immobilized in the vitreous. PEGylation increases the mobility of cationic and larger neutral formulations but does not affect anionic and smaller neutral particles. Convection has a significant role in the pharmacokinetics of nanoparticles, whereas diffusion drives the transport of antibodies. Surface plasmon resonance studies determine that the vitreal corona of anionic formulations is sparse. Proteomics data reveals 76 differentially abundant proteins, whose enrichment is specific to either the hard or the soft corona. PEGylation does not affect protein enrichment. This suggests that protein-specific rather than formulation-specific factors are drivers of protein adsorption on nanoparticles in the vitreous. In summary, our findings contribute to understanding the pharmacokinetics of nanoparticles in the vitreous and help advance the development of nanoparticle-based treatments for eye diseases.

OriginalspråkEngelska
Sidor (från-till)699-713
Antal sidor15
TidskriftMolecular Pharmaceutics
Volym18
Nummer2
DOI
StatusPublicerad - 1 feb. 2021
Externt publiceradJa
MoE-publikationstypA1 Tidskriftsartikel-refererad

Finansiering

S.T., an early stage researcher within the NANOMED project, acknowledges the funding received from the European Union’s Horizon 2020 research and innovation program Marie Skłodowska-Curie Innovative Training Networks (ITN) (grant 676137). SPR and proteomics studies were funded through grants from the Instrumentarium Science Foundation, Inkeri and Mauri Vänskä Foundation, and Drug Research Program Joint Grant. A.S. received support from the Lundbeck Foundation (grant R181-2014-3577) and A.U. from the Academy of Finland (grant 311122). The authors also acknowledge the funding received from Santen Oy. The Light Microscopy Unit of the Institute of Biotechnology at the University of Helsinki is thanked for help with confocal microscopy. M.Sc. Marja Hagström is thanked for assistance in proteomics sample preparation.

Fingeravtryck

Fördjupa i forskningsämnen för ”Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här